Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents
Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Current treatment guidelines indicate that oral antiviral agents for HBeAg-positive chronic
hepatitis B virus infection (CHB) can be stopped if the patient has undergone HBeAg
seroconversion with HBV-DNA loss measured at two consecutive occasions at least 6 months
apart (primary treatment endpoint). Stopping treatment can be considered if undetectable
HBV-DNA has been documented on three separate occasions 6 months apart in HBeAg-negative
patients. However, oral antiviral drugs currently approved for the treatment of CHB have
relatively limited sustained long-term efficacy and a large proportion of patients will
suffer from HBV recurrence after stopping treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital